Trial Profile
The Effect of the ET-1 Receptor Antagonist, Bosentan on Patients With Poorly Controlled Asthma-A 17 Week, Double-Blind, Placebo Controlled Crossover Trial.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Oct 2016
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 27 Oct 2011 Results presented at the 77th Annual Meeting of the American College of Chest Physicians: Chest 2011.
- 08 Oct 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Jan 2009 New trial record